SCHEMBL4471796

SCHEMBL4471796

Cc1ccc(S(=O)(=O)Nc2cccc3cccnc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 10/20 1.00
SLC40A1 Q9NP59 8/20 1.00
KMT2A Q03164 8/20 1.00
AGTR1 P30556 3/20 1.00
LMNA P02545 2/20 1.00
MAPT P10636 2/20 1.00
NPSR1 Q6W5P4 2/20 1.00
MITF O75030 1/20 1.00
S1PR4 O95977 1/20 1.00
ALDH1A1 P00352 1/20 1.00
S1PR1 P21453 1/20 1.00
OPRK1 P41145 1/20 1.00
HTT P42858 1/20 1.00
CKS1B P61024 1/20 1.00
SKP2 Q13309 1/20 1.00
GLO1 Q04760 7/20 0.76
NFKBIA P25963 2/20 0.76
G6PD P11413 1/20 0.76
METAP2 P50579 1/20 0.76
METAP1 P53582 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2337402 0.99 TDP1 (0.97) TDP1SLC40A1KMT2AAGTR1LMNA
SCHEMBL5572103 0.99 TDP1 (0.97) TDP1SLC40A1KMT2AAGTR1LMNA
SCHEMBL15299831 0.99 TDP1 (0.97) TDP1SLC40A1KMT2AAGTR1LMNA
SCHEMBL17067733 0.89 TDP1 (0.81) TDP1SLC40A1KMT2AAGTR1LMNA
SCHEMBL13485950 0.89 SLC40A1 (0.80) TDP1SLC40A1KMT2AAGTR1LMNA
SCHEMBL27214217 0.87 SLC40A1 (0.82) TDP1SLC40A1KMT2AAGTR1LMNA
SCHEMBL30925445 0.87 SLC40A1 (0.82) TDP1SLC40A1KMT2AAGTR1LMNA
SCHEMBL442367 0.87 SLC40A1 (1.00) TDP1SLC40A1KMT2AAGTR1LMNA
SCHEMBL6688368 0.86 SLC40A1 (0.85) TDP1SLC40A1KMT2AAGTR1LMNA
SCHEMBL30553440 0.86 SLC40A1 (0.85) TDP1SLC40A1KMT2AAGTR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1436371-A2 ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING Call, Krimhild (DE) 2004-07-14 EP claimed
WO-2002099023-A2 ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING CALL, KRIMHILD (DE) 2002-12-12 WO claimed
US-11998901-B2 Metal complex, method for producing same, and method for producing gamma-lactam compound using same INSTITUTE FOR BASIC SCIENCE (KR) 2024-06-04 US disclosed
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 US disclosed
US-11691949-B2 Quinoline sulfonamide compounds and their use as antibacterial agents OTAGO INNOVATION LIMITED (NZ) 2023-07-04 US disclosed
US-11691949-B2 Quinoline sulfonamide compounds and their use as antibacterial agents OTAGO INNOVATION LIMITED (NZ) 2023-07-04 US disclosed
CN-111566116-B Novel metal complex, process for producing the same, and process for producing gamma-lactam compound using the same 基础科学研究院 2023-06-09 CN disclosed
US-11413278-B2 Compounds and methods for promoting stress resistance THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-08-16 US disclosed
US-20220168717-A1 NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME INSTITUTE FOR BASIC SCIENCE (KR) 2022-06-02 US disclosed
US-11344872-B2 Metal complex, method for producing same, and method for producing gamma-lactam compound using same INSTITUTE FOR BASIC SCIENCE (KR) 2022-05-31 US disclosed
US-11213701-B2 Neuroprotective quinoline sulfonamides DAHL RUSSELL (US) 2022-01-04 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 US disclosed
EP-1436371-A2 ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING Call, Krimhild (DE) 2004-07-14 EP disclosed
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
EP-0675358-B1 Monitoring water treatment agent in-system concentration and regulating dosage NALCO CHEMICAL CO (US) 2003-07-02 EP disclosed
WO-2002099023-A2 ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING CALL, KRIMHILD (DE) 2002-12-12 WO disclosed
EP-0675358-A1 Monitoring water treatment agent in-system concentration and regulating dosage NALCO CHEMICAL COMPANY (US) 1995-10-04 EP disclosed
US-4209419-A Certain sulfonamidoquinolines, metal complexes thereof, and solutions containing such sulfonamidoquinolines and metal complexes HENKEL CORPORATION (US) 1980-06-24 US disclosed
US-4100163-A Substituted 8-sulfonamidoquinolines GENERAL MILLS CHEMICALS, INC. (US) 1978-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220168717-A1 NOVEL METAL COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING GAMMA-LACTAM COMPOUND USING SAME COASY, NOTUM, MRPL21 TDP1 4645/4885SLC40A1 2128/4885KMT2A 1875/4885
US-11213701-B2 Neuroprotective quinoline sulfonamides SUMO3, SUMO2, PSEN1 TDP1 522/4885SLC40A1 4609/4885KMT2A 2060/4885
US-11691949-B2 Quinoline sulfonamide compounds and their use as antibacterial agents NQO2, SDHA, SIRT5 TDP1 4605/4885SLC40A1 4081/4885KMT2A 1680/4885
US-11344872-B2 Metal complex, method for producing same, and method for producing gamma-lactam compound using same COASY, NOTUM, MRPL21 TDP1 4620/4885SLC40A1 2215/4885KMT2A 1518/4885
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 TDP1 4247/4885SLC40A1 3357/4885KMT2A 1323/4885
US-11998901-B2 Metal complex, method for producing same, and method for producing gamma-lactam compound using same COASY, NOTUM, MRPL21 TDP1 4620/4885SLC40A1 2215/4885KMT2A 1518/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A TDP1 83/4885SLC40A1 4638/4885KMT2A 2234/4885
US-11413278-B2 Compounds and methods for promoting stress resistance HSPA9, ATF4, GPX4 TDP1 2088/4885SLC40A1 1579/4885KMT2A 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.